Mutant GBA1 expression and synucleinopathy risk: First insights from cellular and mouse models

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 195-202

  Sardi, S Pablo ^a   Singh, Priyanka ^b   Cheng, Seng H ^a   Shihabuddin, Lamya S ^a   Schlossmacher, Michael G ^b  

^a SANOFI   (France)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Synuclein; Dementia with Lewy bodies; Gaucher disease; GBA1; Glucocerebrosidase; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE;

ARTICLE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; GAUCHER DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MEMORY DISORDER; MUTANT; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SYNUCLEINOPATHY;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GAUCHER DISEASE; GENE EXPRESSION REGULATION; GLUCOSYLCERAMIDASE; HUMANS; MICE; MUTATION;

EID: 84860216725     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000335038     Document Type: Article

References (32)

1. Sidransky E: Gaucher disease: complexity in a 'simple' disorder. Mol Genet Metab 2004; 83: 6-15.
2. Grabowski GA: Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008; 372: 1263-1271.
3. Velayati A, Yu WH, Sidransky E: The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 2010; 10: 190-198.
4. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alphasynuclein in Lewy bodies. Nature 1997; 388: 839-840.
5. Schlossmacher M: Alpha-synuclein and synucleinopathies; in Growdon J, Rossor MN (eds): The Dementias 2. Oxford, Butterworth Heinemann, Inc, 2007, vol 30, pp 186-215.
6. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schlossmacher MG: Acidβ -glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter/α /e-synuclein processing. Ann Neurol 2011; 69: 940-953.
7. Ron I, Rapaport D, Horowitz M: Interaction between parkin and mutant glucocerebrosidase variants: a possible link between parkinson disease and gaucher disease. Hum Mol Genet 2010; 19: 3771-3781.
8. Manning-Bog AB, Schule B, Langston JW: Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009; 30: 1127-1132.
9. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D: Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37-52.
10. Lieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, Khanna R, Schlossmacher MG, Ringe D, Petsko GA: Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 2007; 3: 101-107.
11. Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA: Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 2011; 102: 436-447.
12. Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, Passini MA, Grabowski GA, Schlossmacher MG, Sidman RL, Cheng SH, Shihabuddin LS: CNS expression of glucocerebrosidase corrects/α /e-synuclein pathology and memory in a mouse model of Gaucher- related synucleinopathy. Proc Natl Acad Sci USA 2011; 108: 12101-1206.
13. Clark LN, Ross BM, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K: Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007; 69: 1270-1277.
14. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T: Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009; 72: 310-316.
15. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, Bar-Shira A, Orr-Urtreger A: Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008; 70: 2277-2283.
16. Westbroek W, Gustafson AM, Sidransky E: Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 2011; 17: 485-493.
17. Cox TM: Gaucher's disease - An exemplary monogenic disorder. QJM 2001; 94: 399-402.
18. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A, Colegial C, Allman JM, Schiffmann R: Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004; 82: 192-207.
19. Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-397.
20. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C: Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002; 110: 1429-1439.
21. Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Mansson JE, Ehinger M, Richter J, Brady RO, Kirik D, Karlsson S: Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci USA 2007; 104: 17483-17488.
22. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E: Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003; 79: 104-109.
23. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E: Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006; 67: 908-910.
24. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW: Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132: 1783-1794.
25. Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, Moaven N, Sidransky E, Lee JC: Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 2011; 286: 28080-28088.
26. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E: Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010; 120: 641-649.
27. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ: The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003; 37: 583-595.
28. Schlossmacher MG, Cullen V, Muthing J: The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2005; 352: 728-731.
29. Balducci C, Pierguidi L, Persichetti E, Parnetti L, Sbaragli M, Tassi C, Orlacchio A, Calabresi P, Beccari T, Rossi A: Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord 2007; 22: 1481-1484.
30. Parnetti L, Balducci C, Pierguidi L, De Carlo C, Peducci M, D'Amore C, Padiglioni C, Mastrocola S, Persichetti E, Paciotti S, Bellomo G, Tambasco N, Rossi A, Beccari T, Calabresi P: Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in dementia with Lewy bodies. Neurobiol Dis 2009; 34: 484-486.
31. Klein C, Krainc D, Schlossmacher MG, Lang AE: Translational research in neurology and neuroscience 2011: Movement disorders. Arch Neurol 2011; 68: 709-716.
32. Sun Y, Quinn B, Witte DP, Grabowski GA: Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J Lipid Res 2005; 46: 2102-2113.